(Adnkronos) - In questo numero: Vaccini fondamentali per la salute dei bambini e per il benessere della comunità Johnson & Johnson e Fondazione mondo digitale Ets lanciano 5a edizione di ‘Fattore J’ L’efficacia di mepolizumab nella granulomatosi eosinofilica con poliangite (Egpa) E ancora Virus respiratorio sinciziale: dai fattori di rischio al vaccino anti-Rsv anche per gli adulti La Fism compie 40 anni e guarda al rilancio del Sistema sanitario nazionale Con ribociclib -28.5% sul rischio relativo di recidiva in donne con tumore della mammella ormonosensibile precoce A seguire la 2° puntata della Serie “Libertà visiva. Un nuovo modo di vedere il mondo” dal titolo: Lenti intraoculari ICL restituiscono libertà visiva senza limiti a chi soffre di miopia e difetti visivi
Category
🗞
NewsTranscript
00:00In this issue, fundamental vaccines for the health of children and for the well-being of the community.
00:17Johnson & Johnson and the ETS Digital World Foundation launch the fifth edition of Fattore J.
00:24The effectiveness of mepolizumab in granulomatosis and eosinophilic with napoleangites and GPA.
00:31And again, syncytial respiratory virus, from the risk factors to the anti-RSV vaccine also for adults.
00:39The FISMO turns 40 and looks at the relaunch of the national health system,
00:44with ribociclib, less than 28.5% recidive in women with precocious hormonal-sensitive mammary tumor.
00:53To follow, the second episode of the series is Liberta Visiva, a new way of seeing the world,
00:58from the title Lenti intraoculari ICL restituiscono liberta visiva senza limiti a chi soffre di myopia e difetti visivi.
01:17The vaccination of newborns is of crucial importance for public health and the well-being of the community.
01:22The first months of life of newborns, in fact, are a particularly vulnerable period,
01:27during which the little ones are exposed to various potentially serious infectious diseases.
01:31A fact underlined in Naples during the Mission Vaccinale Convention,
01:35sponsored by the Italian Pediatric Federation's Campana section,
01:38which made the point on the current state of vaccinations in the region,
01:42highlighting the importance of vaccination coverage for the health of children.
01:46For us pediatricians, there is no difference between mandatory and recommended vaccinations.
01:51On mandatory, there is a stricter control,
01:54because they are the ones that give the child the possibility to access society,
01:58so the school and all the rest.
02:00On the other hand, the recommended ones are the ones, in my opinion, with the greatest impact,
02:05because they are serious diseases, not so incidental, but above all they are very complicated,
02:11because they are serious diseases and we have to distinguish them, not to call them as they once were.
02:17Vaccinations are recommended and not so-called mandatory and optional,
02:23it is no longer an option, it is simply a protection that we want to be given to the child
02:28and therefore we must respect the recommendations for these vaccinations, which are very important.
02:34In Campania, the data on the coverage show encouraging numbers,
02:37with an increase in the adhesion of families to vaccinations,
02:40thanks to the fundamental role of pediatricians.
02:43Today we can say that, regarding mandatory vaccines, the coverage is very, very well covered
02:49and now we are increasing noticeably these recommended vaccinations in this period,
02:55among which we have these last ones, which are really urgent
03:00and which notably improve the vaccination coverage.
03:04I am referring to HPV, meningococcus and also to RSV,
03:08which is going very hard to cover these children who must be vaccinated.
03:15Diseases such as meningitis or pneumonia can have devastating consequences,
03:19but thanks to vaccines, the risk of contracting them is reduced significantly.
03:23Losing this possibility of not vaccinating your children,
03:26putting them at risk of a disease that still exists and when it is present,
03:31it is not a simple disease, it is a disease that often leads to fatal success,
03:35we must increase the adhesion to the vaccination field.
03:41It is logical that for meningitis B, which is a particular vaccine,
03:44it must also be defined in the proposition of the vaccine
03:50and in this there is also the participation of the free choice pediatricians, which is fundamental in my opinion.
03:55With a continuous collaboration between health institutions, pediatricians and families,
03:59it is possible to further improve the vaccination coverage in Campania,
04:03thus guaranteeing effective protection for all children and contributing to a healthier community.
04:09You have to have faith in science, you have to have faith in your pediatrician,
04:14because when there are recommendations,
04:17there are years and decades of studies behind these recommendations,
04:21so they have to trust these proposals and then they can be seen on the field.
04:25We have seen it with papilloma, which is giving excellent results.
04:28Vaccinating a child means preventing a problem.
04:34The role of artificial intelligence in the creation of medicine of the future
04:37The role of artificial intelligence in the creation of medicine of the future
04:41is at the center of the fifth edition of Fattore J,
04:43the initiative of Johnson & Johnson and Fondazione Mondo Digitale TS
04:46that aims to raise awareness among young generations
04:49about the value of innovation in the field of health.
04:52As shown by the survey conducted by SVG for Johnson & Johnson,
04:56over 60% of young people of Generation Z
04:59believe that scientific research and medicine
05:02will have a positive impact on the health of the future
05:05by making it faster, more organized, more effective and personalized.
05:08Fattore J is the fifth edition of our social responsibility project.
05:11As Johnson & Johnson, we bring innovation in many ways,
05:14therapeutic innovation in clinical research,
05:17in development, but above all in health.
05:20It is a project that aims to raise awareness
05:23about the value of health in the field of medicine.
05:26It is a project that aims to raise awareness
05:29about the value of health in the field of medicine,
05:32in clinical research, in development,
05:35but above all we want to take care of information.
05:38Information of the youngest.
05:41So, with this project, we want to try to build a bridge
05:44between the school and the world of health.
05:47It is clear that young people are definitely interested in this concept.
05:50However, we know that we are surrounded by many new things,
05:53artificial intelligence that permeates our daily reality
05:56and that transforms and will transform more and more the world of health.
06:01Already in its previous editions, the project involved a large number of students, institutions and associations.
06:07We have already trained 30,000 students, reached 300,000, in collaboration with 18 patient associations,
06:15more than 180 schools, 5 institutions, research institutes such as the National Institute for Tumors in Milan,
06:23which today hosts us, so a great ecosystem on the health of the country.
06:285. The elements that link technological innovation to oncology, as explained by the director of the National Institute for Tumors,
06:34of which scientific collaboration is supported by Fattore J.
06:37Four are the elements, prevention, screening, assistance, research.
06:43These are all the four elements that have innovation, pharmacological technology and tools within them.
06:49We add a fifth, artificial intelligence.
06:52I believe that artificial intelligence, and these guys on artificial intelligence will have their say,
06:58I believe it could be an additional element to be exploited and used.
07:07With an incidence of 0.5 and 4.2 cases per million people, a prevalence between 10 and 14 cases per million,
07:15the eosinophilic granulomatosis, with polyangiitis and GPA,
07:19is a rare disease that affects blood vessels of small, medium and large sizes, involving several organs.
07:25It is a subdued disease, and for this, for diagnosis, it can take between 7 and 10 years.
07:30Alarm bell, the excessive increase of eosinophils, cells of the immune system.
07:36They are usually patients who have asthma for years, have chronic rhinosinusitis,
07:42often with polyposis, they are operated on 2 or 3 times.
07:46At a certain point, there is an important increase in eosinophils,
07:51and therefore one of the markers, one of the important things to say,
07:56is to always check the eosinophils, a hemochrome with the formula, to see if they are normal or increased.
08:04Because if they increase significantly, like over 5,000, 10,000, 15,000,
08:11they can then infiltrate the organs and therefore there becomes the problem.
08:16At the GPA, already known as Churg-Strauss syndrome, the EGPA press conference was dedicated,
08:22treatment opportunities with mepolizumab and the role of the pneumologist,
08:27organized in Milan by GSK, an appointment in which new therapeutic approaches were also discussed.
08:34The advent of new therapies extremely targeted, such as mepolizumab,
08:38which blocks the circulating interleukin-5, allows us to target in an extremely specific way
08:44the path of type 2 inflammation, rapidly reducing the circulating eosinophil and tissue,
08:51therefore controlling all those eosinophilic manifestations
08:54that characterize the relapses that these patients present.
08:58This therefore allows us to significantly reduce the exposure to cortisone
09:03and clearly improve the quality of life of these patients.
09:06The impact of the EGPA on the life of patients involves both the physical and psychological level,
09:11it is essential for them to have a perspective of care.
09:14Today patients can live a life as normal as possible,
09:19as far as the term can carry difficulties,
09:23and certainly they have a therapeutic horizon, a very different horizon of care compared to a time.
09:3489% of respiratory diseases have been recorded in the over 65 years
09:41for a total of 5,800 people, against a total of 116 up to 4 years of age.
09:47These data emerged from an American study on the mortality rate for RSV between 1999 and 2018,
09:54which underlines that such a virus represents a significant threat to public health,
09:59where adults are perhaps the most at risk.
10:02It was discussed during the press conference of GSK held in Rome,
10:06where it was discussed the threat, the epidemiology of the impact
10:09and the solutions that concern this type of virus.
10:12The RSV is a virus that is transmitted by airway,
10:16by airway from person to person,
10:18and produces effects on the high and low respiratory tracts,
10:23therefore from simple colds to pneumonia, deep bronchitis,
10:30and obviously a respiratory commitment, a respiratory insufficiency,
10:34which according to people, in older people who may have chronic diseases,
10:38other intercurrent diseases, such as morbidity, it really becomes a serious virus.
10:44RSV can also be said to be a really serious virus.
10:50The approval of the adjuvated vaccine against the RSV of GSK
10:55presents a fundamental turning point to protect the vulnerable population
10:59for age or other pathologies,
11:01offering a new tool to defend against this infection.
11:05The characteristics of this vaccine are mainly the fact
11:09that it has been developed specifically for the target population,
11:13and therefore for the adult, elderly population,
11:16with a high level of immunosuppression.
11:19Consequently, both an antigen, a specific antigen,
11:24i.e. the protein F in its conformation of perfusion,
11:28to what is an adjuvant system.
11:30The adjuvant system, in particular the AS01E system,
11:34has been designed specifically to increase the immune response
11:40and therefore provide greater protection to this particularly vulnerable population.
11:45According to the scientific evidence of the HTA study,
11:48the vaccine against the respiratory virus represents an effective technology
11:53for at least three consecutive seasons.
11:55Of this, I would like to clarify, it is the only technology we have given,
11:59so let's say complete.
12:01It is an effective and safe vaccine that protects the individual,
12:04protects the community, and is based on the protection of all
12:07and on the evidence that we have available,
12:09that we hope that our decision-makers can make the right decisions
12:13in the field of protection of the community.
12:15And therefore of anti-RSV vaccination, let's remember it,
12:18a problem not only pediatric, but a problem of adults at risk and of the elderly.
12:23What are the main themes of the HTA study?
12:27Reinforcement of territorial medicine,
12:29training of medical personnel,
12:31prevention, attention to vulnerable areas,
12:34reforms to relaunch and make sustainable the national health system.
12:38These are the main themes addressed during the fourth stage
12:42of the General States of the Federation of Italian Medical Scientific Societies,
12:46which celebrates its 40th anniversary this year.
12:49Preventing is better than curing,
12:51so we had at the Ministry of Health in November
12:55a two-day dedicated to 360 degrees to male and female prevention
13:02that culminated in the village of health,
13:05where we launched the germ,
13:07because our goal was, we want to germinate the culture of prevention
13:15and inform and educate the population.
13:20The event that took place in Rome at the American Center for Studies
13:23was a moment of confrontation on the future of the compartment.
13:26Together with experts from the health sector,
13:28representatives of the federal society and various pharmaceutical companies
13:31and exponents of the political world intervened.
13:34We emphasize the importance of scientific societies.
13:37The FISM, the Medical Scientific Society,
13:42which is the group of all,
13:45has an action of encouragement, support and collaboration
13:49with the national public health system.
13:52For this, a thank you goes to the professionals,
13:54a thank you to Professor Tino Gesualdo,
13:57an idea of health that evidently sees in this great battle
14:02to defend the universalism of our national public health system
14:07and all the players convinced and present
14:11in a battle to defend the fourth national public health system.
14:15The federation brings together about 200 companies with extraordinary quality
14:19and brings together 192,000 health professionals,
14:22figures that will be increasingly central to the definition of future strategies.
14:26Today we face important challenges.
14:29The population is aging, territorial inequalities,
14:35new formulas and new recipes must be implemented.
14:38We are committed on all fronts.
14:41The strengthening of territorial medicine, technological innovation,
14:46the training of staff,
14:48are all fundamental aspects on which we are working.
14:51With the FISM there is a constant, very productive and very profitable dialogue.
14:56We currently have an investigative investigation on health problems.
14:59I am sure that this common work will lead,
15:02if nothing else, to identify the right paths
15:05and then we will all strive to reach the goal.
15:08On the occasion of the Capitolino meeting,
15:10the federal honorary posts were also proclaimed
15:13and the merits of public recognition were conferred to the founding members
15:17and a group of health experts journalists.
15:21What are the benefits of oral therapy?
15:29Oral therapy has obtained the approval of EMA,
15:32the European drug regulatory body,
15:34for the treatment of the early mammary tumor,
15:37positive HR, negative R2,
15:39in a large population of patients at high risk of recidivism.
15:43The approval is based on the study of three phases of birth,
15:46of which updated data have been presented at ESMO,
15:49which have shown how ribociclib,
15:51in combination with inducing endocrine therapy,
15:54offers a clinically significant benefit
15:56in terms of survival free from recidivism.
15:59A therapeutic indication that will allow about twice as many women
16:02with early mammary tumor,
16:04including those with lymph node-free disease,
16:07to benefit from it in Europe,
16:09having at their disposal a new therapeutic option
16:12in two compresses per day for three years,
16:14capable of significantly reducing the risk of recidivism.
16:17During endocrine therapy, in fact,
16:19more than a third of patients with an early mammary tumor diagnosis,
16:22sensitive hormone and advanced stage,
16:24could develop in the years of metastasis in other parts of the body.
16:27As Professor Michelino De Laurentiis,
16:30Director of the Complex Structure of Clinical Oncology, Experimental and Dysenology,
16:34of the National Institute for the Tumor of Giovanni Pasquale of Naples,
16:37underlines in a four-year study,
16:39Nathalie has highlighted a further improvement of the benefit
16:42always in terms of survival free from metastasis,
16:45even after the completion of the three-year treatment period.
16:48The study, carried out in four years,
16:50has shown that this therapy with ribocitlib,
16:53performed with the absorption of two compresses per day for three years,
16:56in addition to standard hormonal therapy,
16:59further reduces the risk,
17:01at the beginning of all other treatments,
17:03of about 29%.
17:05This reduction appears even more marked
17:08in some populations of patients
17:10who could not previously benefit from these additional therapies,
17:14such as those without metastasis of axillary lymphoma,
17:18where even the reduction reaches 34%.
17:22So it is a further step forward
17:25towards our final goal,
17:27which we will soon reach,
17:29which is a 0% risk of recidivism,
17:32which will obviously be equivalent to 100% healing.
17:35For years we have believed that the hormonal-sensitive tumor
17:38was a tumor with good prognosis.
17:40In reality it is, it is not particularly aggressive,
17:43but what is the problem?
17:45That the residues are distributed
17:48along a very, very long time arc.
17:50Today we know that they can also occur
17:52at a distance of 20 or 30 years.
17:55And they go to colonize different organs,
17:58from the starting one, which is the breast,
18:00and they are virtually incurable,
18:02except in a minority of cases.
18:04So it is important to reduce the residues
18:06to increase the definitive healing rates.
18:09A 30-year commitment in clinical research on breast cancer
18:12explains Paola Cuoco,
18:14Medical Affairs Head of Novartis Italy,
18:16a pharmaceutical industry producer of Ribociclib,
18:19which has allowed to improve the quality of life
18:22of thousands of women with breast tumors,
18:24a pathology that affects only in Italy
18:26800,000 people and for 55,000 new diagnoses per year.
18:30The main goal is to find
18:33increasingly innovative therapeutic solutions.
18:36Novartis is committed in clinical research
18:39with more than 240 clinical studies every year.
18:44Obviously this alone is not enough,
18:48an active collaboration is necessary
18:51with all stakeholders of the health system
18:54in order to investigate more and more
18:58the unmet needs of patients,
19:00in order to go more and more
19:03towards a personalization of treatment
19:07and towards the possibility
19:09that these treatments can then
19:12actually reach the patient's bed,
19:16also through partnerships
19:18with associations and institutions
19:21that allow an increasingly equal access to care.
19:37An advanced and effective solution
19:41to correct visual defects such as myopia,
19:44in particular in cases from moderate to severe,
19:47is what the intraocular lenses, ICL, represent.
19:51Thanks to a quick and safe intervention, in fact,
19:54this innovative technology is able to offer
19:57a permanent correction and a natural vision,
20:00giving patients the opportunity to live
20:03without the need for glasses or contact lenses.
20:06Contrary to what one might think,
20:09these lenses were perfect only for high values
20:12of myopia or hypermetropia.
20:14The range is around 18 diopteries for myopias
20:17and 8 diopteries for hypermetropia,
20:19also associated with astigmatic components.
20:22In fact, for many years I have adopted
20:25the system of this lens
20:27also for patients with medium myopias,
20:29patients who often have a clearly superior
20:32vision compared to any laser method.
20:35And above all, it allows me to embrace
20:38all those types of patients
20:40who cannot be operated with the laser,
20:43such as patients with eye dryness,
20:45general pathologies, very thin corns,
20:48or even pathologies such as keratoconus,
20:51perhaps in the first stage,
20:53which cannot be operated with the laser,
20:56if not with special techniques,
20:58while they can have a wonderful result
21:01through the ECL.
21:03What makes this technology distinctive
21:05is its ability to guarantee excellent visual quality
21:08even in conditions of poor brightness,
21:10such as night vision.
21:12Moreover, the reversibility of the intervention
21:15and the speed of recovery
21:17make it a highly appreciated choice by patients
21:20with a satisfaction rate that reaches 99.4%
21:24and it is a relatively fast intervention.
21:27It is done in topical anesthesia,
21:29only with a drop supply.
21:31It requires a collaboration from the patients,
21:34so this is another very important selection criterion.
21:37Then, through a 2.75 mm micro-incision,
21:42a liquid is introduced to inflate the front chamber of the eye
21:46to create a space to be able to put this lens,
21:49prior to dilation of the patient,
21:52lens that will be placed behind the iris
21:54and in front of the crystalline,
21:56so that when the iris closes,
21:58also visibly no patient or no person
22:01realizes that the patient has something inside the eye.
22:05The intervention can take 5-10 minutes on average,
22:09but it is not a problem of speed.
22:11The important thing is to do each maneuver well,
22:14in the right way.
22:15Thanks to the ECL lenses,
22:17the quality of life of those suffering from myopia,
22:19like Gabriele, is significantly improved.
22:22I feel really good without glasses.
22:26For me it's a dream,
22:27after spending many years without glasses,
22:30so I'm very happy to have done this intervention.
22:34I didn't even realize the timing,
22:36because it was really about 5 minutes,
22:39something like that,
22:40but very fast, really.
22:43I didn't feel pain, nothing, perfect.
22:46It's a beautiful feeling,
22:48because once I struggled to get to certain characters,
22:53and now to get to 7, 8, 9, 10,
22:56for me it's a great achievement, really.
23:00And I thank Dr. Piotri
23:03who gave me this beautiful gift.
23:07Thank you!
23:14This was our latest news.
23:16To contact us,
23:17you can write to salutechioccioladinecronos.com
23:20Thank you for following us
23:22and see you next time!